Tablet app tracks eye movements to spot chemo brain
NCT ID NCT05186948
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to develop and validate a tablet-based eye-tracking app to detect cancer-related cognitive impairment, often called 'chemo brain.' Researchers planned to enroll 230 participants, including breast cancer patients scheduled for chemotherapy and healthy volunteers. The app would track eye movements to measure attention and processing speed. However, the study was terminated early, so its effectiveness remains unproven.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Eye-tracking software application
What this could lead to
If successful, this could provide a simple, non-invasive way to detect and monitor brain fog in cancer patients using just a tablet.
What could go wrong
The study was terminated early, so results are limited. It is a small, early-stage development, and the technology may not prove accurate enough for clinical use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER-RELATED COGNITIVE IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
McGill University Health Center-Cedar Cancer Center
Montreal, Quebec, H4A 3J1, Canada